A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib
Related Experiment Video
Updated: Feb 12, 2026

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
Published on: May 1, 2020
Olivia M Lucero, Sarah Fitzmaurice, Curtis Thompson
1Departments of Dermatology, Oregon Health & Sciences University, Portland, Oregon.
Abstract:
Vismodegib is a small molecule inhibitor of the Hedgehog signaling pathway that has shown efficacy in the control of locally advanced or metastatic basal cell carcinoma, although proof of its effectiveness in the elimination of aggressive tumors is lacking. We report a case and provide complete histological evidence of a 69-year-old gentleman who presented with a recurrent, infiltrative, and sclerosing (morpheiform) basal cell carcinoma on his left upper lip that was entirely eradicated with a three-month course of vismodegib 150 mg daily. Complete histologic clearance of a tumor in a recurrent, infiltrative, and sclerosing basal cell carcinoma with vismodegib is uncommon.
Insights
Vismodegib effectively eradicated an aggressive basal cell carcinoma. This case provides histological evidence of complete tumor clearance, offering hope for difficult-to-treat BCC cases.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Vismodegib inhibits the Hedgehog signaling pathway.
- It shows efficacy in advanced basal cell carcinoma (BCC).
- Complete tumor eradication evidence is limited.
Observation:
- A 69-year-old male presented with recurrent, infiltrative, and sclerosing (morpheiform) BCC on his upper lip.
- This BCC subtype is known for its aggressive nature and resistance to conventional therapies.
Findings:
- A three-month course of vismodegib (150 mg daily) resulted in complete eradication of the BCC.
- Histological examination confirmed the absence of tumor cells, providing definitive evidence of clearance.
- Complete histological clearance of aggressive BCC with vismodegib is rarely documented.
Implications:
- Vismodegib demonstrates potential for complete tumor elimination in aggressive BCC subtypes.
- This case highlights the importance of histological confirmation for treatment efficacy.
- Further research into vismodegib for morpheiform BCC is warranted.
Related Concept Videos
Aggression
Ecological Succession
Laminins are the Adhesive Proteins of Basal Lamina
In humans, the five forms of alpha chains are LAMA 1, LAMA 2, LAMA 3, LAMA 4, and LAMA 5. The four forms of beta chains are LAMB 1, LAMB 2, LAMB 3, and LAMB 4. The three forms of gamma...
Location and Orientation of the Heart
Basal Lamina are the Specialized Form of ECM
Proteins...
Type IV Collagen of Basal Lamina
A type IV collagen molecule has six alpha chains which can...

